India, June 16 -- Invivyd, Inc. (IVVD), a commercial-stage biopharmaceutical company, announced completion of participant enrollment in the Phase 3 LIBERTY clinical trial of VYD2311 for the COVID-19 indication.
VYD2311 is an investigational monoclonal antibody or mAb candidate designed to neutralize contemporary virus lineages, especially SARS-CoV-2 or COVID-19. The FDA granted fast-track designation for VYD2311.
LIBERTY is a Phase 3, randomized, double-blind study designed to evaluate the safety, serum virus-neutralizing antibody responses, and pharmacokinetics of VYD2311. This includes an investigational monoclonal antibody treatment, an mRNA COVID-19 vaccine, and the co-administration of VYD2311 with the mRNA vaccine.
The primary endp...